Bombay O Blood Donations in Sri Lanka: A Descriptive Study
Journal of Tropical Health · 2025
DOI: 10.4038/joth.v1i3.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Tropical Health, 2025. Verfasst von Samantha Senavirathna. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In addition to the four main groups of the ABO blood group system, a rare phenotype called Bombay O exists. When blood is needed from the Bombay O blood group for a patient, it is challenging for the transfusion service and understanding the prevalence of donors for Bombay O blood group is beneficial.
Objectives
The objectives of this study were to identify the number of Bombay O blood donations in Sri Lanka and determination of the trend in Bombay O blood donation.
Methods
The study was conducted using annual blood collection statistics of the National Blood Transfusion of Sri Lanka, from 2016 to 2024.
Results
Bombay O blood donation remains less than 0.01% of total blood collection in Sri Lanka. Even though there is a rise in total blood donations from 414175 to 454767, there is no increment in Bombay O blood donors. Furthermore, cryopreservation of Bombay O red cells has become increasingly available to maintain an adequate stock of Bombay O blood.
Conclusion
Similar to the other countries in the region, Bombay O blood donations in Sri Lanka are very low, as less than 0.01%. Hence, other strategies must be implemented to manage the patients who need Bombay O blood.
Zitieren
APA
Senavirathna, S. (2025). Bombay O Blood Donations in Sri Lanka: A Descriptive Study. Journal of Tropical Health. https://doi.org/10.4038/joth.v1i3.11
Vancouver
Senavirathna S. Bombay O Blood Donations in Sri Lanka: A Descriptive Study. Journal of Tropical Health. 2025. doi:10.4038/joth.v1i3.11
BibTeX
@article{Senavirathna2025,
author = {Senavirathna, Samantha},
title = {Bombay O Blood Donations in Sri Lanka: A Descriptive Study},
journal = {Journal of Tropical Health},
year = {2025},
doi = {10.4038/joth.v1i3.11}
}
EUVIMED